Phaseline

Companies › Broadenbio

Broadenbio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BB102
FGFR4 inhibitor
FGFR4Phase 1Advanced Solid TumorDec 2026
BB3008–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06143007BB3008Phase 1Advanced Solid TumorOncologyMay 2025
NCT06258408BB102Phase 1Advanced Solid TumorOncologyDec 2026

Targets

FGFR4 (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Taiho Oncology Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing) Tyra Biosciences Biohaven Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.